Patients with RA who have used b/tsDMARDs demonstrated similar risks for multiple myeloma when compared with those taking only csDMARDs.
Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.
An elderly patient who was initially suspected of having antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) was instead diagnosed with multiple myeloma, according to a case report ...
Zacks Investment Research on MSN6d
Regeneron Gets Positive CHMP Opinion for Multiple Myeloma DrugRegeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European ...
MedPage Today on MSN6d
The Basics of Multiple MyelomaIn spite of recent advances in the management of multiple myeloma, cure has been elusive, with efforts to improve long-term outcomes thwarted by repeated cycles of relapse and remission. This is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback